BioCardia, Inc.BCDAEarnings & Financial Report
BioCardia, Inc. is a clinical-stage biotechnology company specializing in regenerative therapies for cardiovascular diseases. It develops cell and gene therapy candidates targeting heart failure, myocardial infarction, and other cardiac disorders, serving patients across North America and global cardiology care segments, with a focus on improving long-term cardiac function for underserved patient populations.
Revenue
$3.0K
Gross Profit
N/A
Operating Profit
$-1.6M
Net Profit
$-1.6M
Gross Margin
N/A
Operating Margin
-54966.7%
Net Margin
-54866.7%
YoY Growth
-93.0%
EPS
$-0.88
BioCardia, Inc. Q2 FY2024 Financial Summary
BioCardia, Inc. reported revenue of $3.0K (down 93.0% YoY) for Q2 FY2024, with a net profit of $-1.6M (up 51.9% YoY) (-54866.7% margin).
Key Financial Metrics
| Total Revenue | $3.0K |
|---|---|
| Net Profit | $-1.6M |
| Gross Margin | N/A |
| Operating Margin | -54966.7% |
| Report Period | Q2 FY2024 |
BioCardia, Inc. Annual Revenue by Year
BioCardia, Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $0).
| Year | Annual Revenue |
|---|---|
| 2025 | $0 |
| 2024 | $58.0K |
| 2023 | $477.0K |
| 2022 | $1.4M |
BioCardia, Inc. Quarterly Revenue & Net Profit History
BioCardia, Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $0 | — | $-2.0M | N/A |
| Q3 FY2025 | $0 | — | $-1.5M | N/A |
| Q2 FY2025 | $0 | — | $-2.0M | N/A |
| Q1 FY2025 | $0 | — | $-2.7M | N/A |
| Q4 FY2024 | $0 | — | $-2.3M | N/A |
| Q3 FY2024 | $0 | — | $-1.7M | N/A |
| Q2 FY2024 | $3.0K | -93.0% | $-1.6M | -54866.7% |
| Q1 FY2024 | $55.0K | -14.1% | $-2.3M | -4121.8% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $55000 | $3000 | $0 | $0 | $0 | $0 | $0 | $0 |
| YoY Growth | -14.1% | -93.0% | N/A | N/A | N/A | N/A | N/A | N/A |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $2.7M | $2.9M | $6.3M | $3.7M | $2.2M | $2.1M | $6.1M | $3.4M |
| Liabilities | $5.0M | $4.9M | $3.5M | $2.9M | $3.7M | $4.0M | $3.5M | $2.5M |
| Equity | $-2.3M | $-2.0M | $2.8M | $837000 | $-1.5M | $-1.9M | $2.6M | $895000 |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-1.5M | $-1.3M | $-2.6M | $-2.4M | $-1.6M | $-1.6M | $-1.7M | $-2.5M |